Vidofludimus Calcium Phase 3 Trial to Advance in 2026
Researchers will present trial plans for a potential multiple sclerosis treatment on November 5, 2026.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Do you trust pharmaceutical companies to prioritize effective treatments for chronic progressive diseases?
Immunic will host a virtual Research and Development Day on November 5, 2026, to outline plans for an upcoming Phase 3 trial. This event will provide clinical and scientific details regarding the potential use of vidofludimus calcium for progressive multiple sclerosis.
Why it matters
People living with progressive multiple sclerosis currently face limited treatment options, and this presentation will detail how the investigational drug may address these unmet needs. The session aims to explain the potential neuroprotective effects of the therapy.
The drug candidate, vidofludimus calcium, is advancing to Phase 3 testing based on its mechanism as a Nurr1 activator. Efficacy and safety outcomes for this target population have yet to be determined in a formal clinical trial setting.
The players
Immunic
A biotechnology company focused on developing therapies for chronic inflammatory and neurodegenerative diseases.
Jiwon Oh
A researcher and clinician at the University of Toronto specializing in multiple sclerosis.
Maria Pia Sormani
A researcher at the University of Genoa with expertise in clinical trial methodology and statistics in neurology.
The details
Vidofludimus calcium functions as a Nurr1 activator, a biological pathway researchers believe may promote neuroprotective effects. The upcoming presentation will outline the specific clinical and scientific rationale for testing this approach in patients with progressive multiple sclerosis. The trial is scheduled to initiate later in 2026.
Timeline
November 5, 2026: Immunic hosts a virtual Research and Development Day.
Late 2026: The company plans to initiate the Phase 3 clinical trial.
Health Landscape
The development of therapies for progressive multiple sclerosis remains a primary focus of neuroimmunology, as many existing treatments primarily target relapsing forms of the condition. This trial represents an effort to bridge the gap in available neuroprotective treatment options.
This development is in the clinical research phase and is not currently available for patient use. Individuals interested in ongoing multiple sclerosis research should discuss the potential for future trial participation or new treatment options with their neurologist.
The takeaway
Advancements in Nurr1 activation research may eventually offer new ways to address neurodegeneration in progressive multiple sclerosis. Keep track of clinical trial registry updates if you are looking to understand the availability of emerging research opportunities.
What happens next
The company expects to initiate the Phase 3 trial in late 2026.
Further reading
For broader insights on neurodegenerative conditions and research progress, visit our Alzheimer’s section.
Source note: This article includes information reported by Proactiveinvestors NA.
Live Poll
Do you trust pharmaceutical companies to prioritize effective treatments for chronic progressive diseases?
